Technology

An mRNA platform built to reach the undruggable.

Our cells use messenger RNA to translate genes into proteins. ValamAi’s technology uses mRNA to direct a patient’s own cells to manufacture functional proteins — helping the body heal itself.

How it works

From sequence to therapeutic protein

Design

We modify mRNA coding information — including proprietary signal peptides — to control the translation, processing and secretion of disease-related proteins.

Deliver

The mRNA is applied locally, by injection into the target tissue or as a topical formulation on the skin.

Express

The patient’s own cells translate the mRNA and secrete the therapeutic protein where it is needed most.

Protein Secretion Pillar

Cells that manufacture their own medicine

Our cells use messenger RNA (mRNA) to translate DNA (genes) into proteins which are required for the healthy function of the human body. Expression of disease-relevant proteins can be achieved by molecular targeting of a specific gene through mRNA. ValamAi’s technology aims to use mRNA to direct a patient’s cells to manufacture their own functional proteins and help the body heal itself to protect against disease.

ValamAi has discovered and developed ways to optimize protein production and secretion through employing modifications in mRNA coding information, thereby controlling the translation and processing of disease-related proteins. Its platform technology offers the potential to produce several new molecular entities that show different tissue specificity for one therapeutic target — ensuring the full exploration of its therapeutic value in different tissues and hence disease areas.

ValagileValamAi’s mRNA technology platform

AUG·GCC·ACC

In-vitro proof of concept in different tissues and targets

Enhanced protein targeting

Higher mRNA potency

In-vivo proof of concept in tissue injury

Multi-Protein Target Pillar

Several therapeutic targets in one molecule

The multi-protein platform focuses on RNA molecules that simultaneously target more than one therapeutic protein, thereby up- and/or down-regulating these proteins independently. With the multi-protein platform, ValamAi is capable of applying linked and synergistic therapeutic concepts — e.g. immunomodulatory, anti-inflammatory and pro-regenerative mechanisms — within one drug candidate.

Given the immense potential of combinatory therapeutic approaches, ValamAi is exploring oncology to validate its multi-protein platform in cancer therapies. The team is applying the combinatory approach to target scientifically established mechanisms associated with cancer progression, metastasis or chemoresistance in one therapeutic molecule. The biological mechanisms targeted by these molecules are expected to apply to multiple tumor types.

Topical Dermatology Pillar

RNA medicine, applied to the skin

Topical treatment is strongly preferred over systemic therapy in dermatology, yet topical formulations have historically been limited to small molecules — leaving roughly 85–90% of proteins undruggable by classical small-molecule approaches. ValamAi is extending its mRNA platform into a topical RNA cream format, opening up precision dermatology targets such as androgenetic alopecia, acne, melasma, wrinkles, psoriasis, atopic dermatitis and vitiligo that are otherwise difficult to reach.

RNA therapies make every target druggable. Combining RNA with topical formulation and cosmetics-adjacent applications is a novel, largely uncontested niche for ValamAi, with the potential for reduced regulatory hurdles relative to systemic RNA therapies.

See the platform in action

Our technology is already powering programs from discovery through FDA IND clearance.

Explore the pipeline